Russell Investments Group Ltd. Has $552,000 Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

Russell Investments Group Ltd. lifted its position in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 3,471.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 44,648 shares of the company's stock after acquiring an additional 43,398 shares during the period. Russell Investments Group Ltd.'s holdings in Wave Life Sciences were worth $552,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Loomis Sayles & Co. L P bought a new stake in Wave Life Sciences during the fourth quarter valued at about $20,545,000. Vanguard Group Inc. boosted its stake in Wave Life Sciences by 10.2% during the 4th quarter. Vanguard Group Inc. now owns 3,182,512 shares of the company's stock valued at $39,368,000 after purchasing an additional 294,956 shares during the period. Geode Capital Management LLC grew its holdings in Wave Life Sciences by 14.3% in the 3rd quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company's stock valued at $18,615,000 after buying an additional 283,419 shares during the last quarter. Emerald Advisers LLC increased its position in Wave Life Sciences by 9.7% in the 4th quarter. Emerald Advisers LLC now owns 3,162,369 shares of the company's stock worth $39,119,000 after buying an additional 280,859 shares during the period. Finally, Principal Financial Group Inc. acquired a new position in Wave Life Sciences during the 4th quarter valued at $3,076,000. Hedge funds and other institutional investors own 89.73% of the company's stock.

Insiders Place Their Bets

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the transaction, the director now owns 16,115 shares of the company's stock, valued at $157,443.55. This represents a 39.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares of the company's stock, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 29.10% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price objective on shares of Wave Life Sciences in a report on Wednesday, March 26th. Wedbush started coverage on Wave Life Sciences in a report on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 price target for the company. Jefferies Financial Group started coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price objective on the stock. Finally, StockNews.com upgraded Wave Life Sciences from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $22.18.

Wave Life Sciences Stock Down 0.5 %

NASDAQ WVE traded down $0.03 during trading on Monday, reaching $6.70. 516,768 shares of the stock traded hands, compared to its average volume of 1,212,713. The stock's 50-day moving average price is $8.49 and its 200 day moving average price is $11.54. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -5.95 and a beta of -0.93. Wave Life Sciences Ltd. has a fifty-two week low of $4.25 and a fifty-two week high of $16.74.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.34. The firm had revenue of $83.75 million for the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. Analysts anticipate that Wave Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.